NEW YORK – Immunocore yatangaje ko kuwa mbere izagurisha imigabane 3,733,333 mu masezerano yo gushora imari mu migabane y’abikorera (PIPE) yitezweho gukusanya miliyoni 140 z’amadolari.
Muri ayo masezerano, Immunocore izagurisha imigabane yayo rusange n’imigabane idatora ku giciro cya $37.50 kuri buri mugabane. Abashoramari basanzwe b’iyi sosiyete bitabiriye iyi nkunga barimo RTW Investments, Rock Springs Capital na General Atlantic. Biteganijwe ko amasezerano ya PIPE azarangira ku ya 20 Nyakanga.
Iyi kompanyi izakoresha amafaranga izakura mu gutera inkunga abakandida bayo ba kanseri n’indwara zandura, harimo no guteza imbere umukandida wayo ukomeye wa kanseri, Kimmtrak (tebentafusp-tebn), mu kuvura uruhu rwa HLA-A*02:01 rufite melanoma nziza y’uruhu na uveal. Iyi nkunga, hamwe n’amafaranga azava muri Kimmtrak, biteganijwe ko izatera inkunga ibikorwa bya Immunocore kugeza mu 2025.
Muri uyu mwaka, Kimmtrak yemerewe gukoreshwa ku barwayi ba melanoma idakira ya HLA-A * 02:01 cyangwa idashobora kuvurwa muri Amerika, i Burayi no mu Bwongereza, hamwe n'ibindi bihugu. Immunocore ikomeje kwiga uyu muti mu nyigo yakozwe mu cyiciro cya mbere/icya kabiri muri melanoma y'uruhu ya HLA-A * 02:01.
Immunocore irimo kandi guteza imbere indi miti ine ya kanseri, harimo n'indi miti ibiri ya T-cell receptor mu igeragezwa rya Phase I/II mu ndwara zikomeye. Umwe muri iyo miti uri gukorwa ku barwayi ba HLA-A*02:01-positive na MAGE-A4-positive, naho undi ukaba wibasira kanseri ya HLA-A*02:01 na PRAME-positive. Iyi sosiyete ifite kandi imiti ibiri ya kanseri itaratangazwa mu isuzuma ry’ibanze.
Politiki y'ibanga.amategeko n'amabwiriza. Uburenganzira © 2022 GenomeWeb, ishami ry'ubucuruzi rya Crain Communications. uburenganzira bwose burasubitswe.